2-Methyl-iPALT

Last updated

2-Methyl-iPALT
2-Methyl-iPALT.svg
2-Methyl-iPALT 3D.png
Clinical data
Other names2-Me-iPALT; 2-Methyl-ALiPT; 2-Me-ALiPT; ASR-3002; ASR3002; 2-Methyl-N-isopropyl-N-allyltryptamine; 2-Methyl-N-allyl-N-isopropyltryptamine
Drug class Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist
ATC code
  • None
Identifiers
  • N-[2-(2-methyl-1H-indol-3-yl)ethyl]-N-prop-2-enylpropan-2-amine
CAS Number
PubChem CID
Chemical and physical data
Formula C17H24N2
Molar mass 256.393 g·mol−1
3D model (JSmol)
  • CC1=C(C2=CC=CC=C2N1)CCN(CC=C)C(C)C
  • InChI=1S/C17H24N2/c1-5-11-19(13(2)3)12-10-15-14(4)18-17-9-7-6-8-16(15)17/h5-9,13,18H,1,10-12H2,2-4H3
  • Key:QXAIQMVRYZDEJS-UHFFFAOYSA-N

2-Methyl-iPALT, or 2-methyl-ALiPT, also known as 2-methyl-N-isopropyl-N-allyltryptamine or by its developmental code name ASR-3002, is a serotonin receptor modulator of the tryptamine family. [1] It is the 2-methyl derivative of iPALT. [1] The drug is very similar in structure to 2-methyl-DiPT, which Alexander Shulgin hypothesized would be a DiPT-like selective auditory hallucinogen but never synthesized nor tested. [1]

Contents

Pharmacology

Pharmacodynamics

2-Methyl-iPALT is a non-selective serotonin receptor agonist, including of the serotonin 5-HT1B, 5-HT2A, 5-HT2B, and 5-HT6 receptors, but not of the serotonin 5-HT1A receptor. [1] However, it shows rather low, micromolar potency for most of these actions, with for example 264-fold lower potency as a serotonin 5-HT2A receptor agonist than the known psychedelic drug 5-MeO-iPALT (ASR-3001). [1] The drug is inactive as a monoamine reuptake inhibitor. [1]

Chemistry

Synthesis

The chemical synthesis of 2-methyl-iPALT has been described. [1]

Analogues

Analogues of 2-methyl-iPALT include 5-MeO-iPALT (ASR-3001), 4-HO-iPALT, 2-methyl-DMT, 2-methyl-DET, and 2-methyl-DiPT, among others. [1] [2]

History

2-Methyl-iPALT was patented by the Alexander Shulgin Research Institute (ASRI) in 2024. [1]

See also

References

  1. 1 2 3 4 5 6 7 8 9 US 20240277665A1,Daley PF, Cozzi NV, Callaway WB,"Asymmetric allyl tryptamines",issued 4 March 2024, assigned to Alexander Shulgin Research Institute Inc.
  2. ↑ Shulgin A, Shulgin A (September 1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. ISBN   0-9630096-9-9. OCLC   38503252.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.